Month: November 2020

SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present three posters at European Society of Intensive Care Medicine (ESICM) LIVES 2020, which takes place virtually Dec. 6-9, 2020.Cidara will highlight analyses from the completed Phase 2 STRIVE trial of rezafungin for treatment of candidemia and/or invasive candidiasis. Rezafungin is a novel once-weekly echinocandin currently in pivotal Phase 3 trials for the treatment and prevention of serious fungal infections. New findings from the STRIVE trial related to intensive care unit (ICU) status will be shared in the poster presentation as follows:Title: Analysis...

Patient screening and dosing ongoing in Turkey and HungaryTopline data expected in Q2 2021 for the Combination TrialDELRAY BEACH, Fla., Nov. 30, 2020 (GLOBE NEWSWIRE) — AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that the first two patients have been dosed in Turkey for its Phase 2 trial evaluating its investigational drug, MS1819, in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy (PERT), for the treatment of severe exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF).“In the midst of a global pandemic and unpredictable obstacles, we are very encouraged to see our Combination therapy trial moving forward...

AUSTIN, Texas, Nov. 30, 2020 (GLOBE NEWSWIRE) — Vital Farms (Nasdaq: VITL), a Certified B Corporation that offers a range of ethically produced pasture-raised foods nationwide, today announced that Russell Diez-Canseco, President and Chief Executive Officer, and Jason Dale, Chief Financial Officer and Chief Operating Officer, will present at two upcoming virtual investor conferences. The conference details include:On Thursday, December 3, 2020, Diez-Canseco and Dale will host a fireside chat at the Morgan Stanley Global Consumer & Retail Conference. The fireside chat will take place at 1:00 p.m. ET, or 12:00 p.m CT. Participants may access the live webcast under the “Events & Presentations” tab on the Vital Farms Investor Relations site: https://investors.vitalfarms.com/investor-relations. Following the discussion, a replay...

VANCOUVER, British Columbia, Nov. 30, 2020 (GLOBE NEWSWIRE) — Candente Copper Corp. (TSX:DNT, BVL:DNT) (“Candente Copper”, “Company”) is pleased to announce that the Company has entered into an Assignment Agreement (“AA”) with Forte Copper Corp. (“Forte Copper”), on the Don Gregorio copper-gold porphyry project.The Company entered into an Option Agreement on the Don Gregorio project with Forte Copper (previously known as Plan B Minerals) in 2017. The recently signed Assignment Agreement allows Forte Copper to move ahead with applications for drilling permits.Under the Assignment and Option Agreements Forte Copper has the right to earn a 60% interest in the Don Gregorio property by completing the following terms:Making payments of US$500,000 to Candente; andDrilling 10,000 metres within three years of receiving drilling permits...

THE WOODLANDS, Texas, Nov. 30, 2020 (GLOBE NEWSWIRE) — Conn’s, Inc. (NASDAQ: CONN) (“Conn’s” or the “Company”) today announced that it has commenced a cash tender offer (the “tender offer”) to purchase up to $100.0 million aggregate principal amount (as it may be increased, the “tender cap”) of its outstanding 7.250% Senior Notes due 2022 (CUSIP Nos. 208242 AB3) (the “notes”). The tender offer is being made upon the terms and subject to the conditions described in the Company’s Offer to Purchase dated November 30, 2020 (the “Offer to Purchase”). The tender offer will expire at 11:59 p.m., New York City time, on December 28, 2020, unless extended or earlier terminated by Conn’s (such time and date, the “expiration date”). Tenders of notes may be withdrawn at any time prior to 5:00 p.m., New York City time, on December 11, 2020 (the...

RECORDATI:  MARKET AUTHORIZATION APPLICATION FOR ARS-1 (EPINEPHRINE NASAL SPRAY) ACCEPTED BY EUROPEAN MEDICINES AGENCYMilan, 30 November 2020 – Recordati announces that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application (MAA) submission by ARS Pharmaceuticals for review of ARS-1 (known as NeffyTM in the USA), an epinephrine nasal spray for the emergency treatment of severe allergic reactions, including anaphylaxis. On 21 September 2020 Recordati announced the signing of an exclusive license agreement with ARS Pharmaceuticals, a private U.S. company, for the commercialization of ARS-1 in 93 countries including those in the European Union.The MAA submitted to EMA includes data from multiple clinical studies showing that 1 mg of ARS-1 achieves epinephrine exposures that are similar to a 0.3 mg epinephrine...

RECORDATI: ACCETTATA DALLA EUROPEAN MEDICINES AGENCY LA PRESENTAZIONE DELLA RICHIESTA DI AUTORIZZAZIONE ALL’IMMISSIONE IN COMMERCIO PER ARS-1 (SPRAY NASALE A BASE DI EPINEFRINA)Milano, 30 novembre, 2020 – Recordati annuncia che la European Medicines Agency (EMA) ha accettato la presentazione di una Richiesta di Autorizzazione all’Immissione in Commercio da parte di ARS Pharmaceuticals per ARS-1 (Neffy™ negli Stati Uniti d’America), uno spray nasale a base di epinefrina per il trattamento in emergenza di reazioni allergiche gravi che potrebbero portare all’anafilassi. Il 21 settembre 2020 Recordati ha annunciato la firma di un accordo esclusivo di licenza con ARS Pharmaceuticals, una società farmaceutica privata basata negli Stati Uniti d’America, per la commercializzazione di ARS-1 in 93 paesi compresi quelli dell’Unione Europea.La richiesta...

TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) — Pasinex Resources Limited (CSE: PSE) (FSE: PNX) (The “Company” or “Pasinex”) today reports the Company’s financial and operating results for the three and nine months ended September 30, 2020.Andrew Gottwald, Chief Financial Officer of Pasinex, commented, “There were positive developments during the quarter at the Company’s Turkish joint venture including management changes, the beginning of the development of a fourth adit and the addition of the Mahyalar claim. We are also very pleased to have been able to negotiate an extension on the highly prospective Gunman project option. 2020 has proved to be a challenging year, but the Company is now positioned to drive both of these interests forward in 2021.”Highlights – Third Quarter 2020Financial and OperationalFor the three and nine months...

WALL, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) — BIO-key International, Inc. (NASDAQ: BKYI), an innovative provider of identity and access management (IAM) solutions powered by biometrics, today announced the launch of PortalGuard IDaaS, bringing the power of its award-winning PortalGuard identity and access management (IAM) platform to the cloud as a fully-hosted, scalable and secure identity-as-a-service (IDaaS) offering. PortalGuard IDaaS is operational, having already processed millions of authentication transactions for customers.PortalGuard IDaaS includes BIO-key’s NIST-certified device-or-server biometric authentication factors, along with fourteen other options for flexible authentication. PortalGuard IDaaS is already operational, having processed millions of authentication transactions for customers. As the demand for always-on...